ARTCLINE erreicht Meilenstein bei septischem Schock: Rekrutierung der ReActIF-ICE-Studie erfolgreich abgeschlossen
ARTCLINE achieves milestone in septic shock: Patient recruitment for the ReActIF-ICE study successfully completed
ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy
100 patients already enrolled: ARTCLINE reports rapid progress in multicenter clinical study on immune support in septic shock (ReActIF-ICE)
ARTCLINE Establishes Scientific Advisory Board with Leading Experts from Nephrology, Intensive Care and Transfusion Medicine
ARTCLINE appoints Dirk Hessel as Managing Director and Prepares the Market Entry for Innovative Septic Shock Treatment
First Patients enrolled in EU randomized Trial of ARTCLINEs Immune-cell Therapy System for treatment of septic shock
ARTCLINE receives 4 million euros and starts clinical trial with novel immune cell therapy for septic shock patients
